Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Director dealings: Bridgepoint head partner invests, Staffline non-exec linked to transactions

(Sharecast News) - Bridgepoint Group was at the top of the list of director purchases on Thursday after its group managing partner picked up almost £0.2m worth of shares. The FTSE 250 company said Jonathan Raoul Hughes bought 40,000 shares on 21 September in a single transaction on the London Stock Exchange.

Hughes paid 197.67p for each share, valuing the transaction at £195,240.00.

Elsewhere, Staffline Group was in focus among Thursday's disclosures after reporting that on 18 September, Henry Spain Investment Services - a person closely associated with non-executive director and interim chairman Thomas Spain - transferred out 1,514,050 shares valued at a unit cost of 28p each.

Therefore, its notifiable interest was reduced by 1,514,050 shares.

Separately, on 20 September, Henry Spain Investments purchased 600,000 shares at 28.69p apiece.

The notifiable interest of Henry Spain had thus decreased to 31,498,700 shares, which is 20.57% of the ordinary shares in issue.

At the close on Thursday, shares in Bridgepoint Group were down 1.27% at 194.5p, while those in Staffline Group were flat at 29.1p.

Reporting by Josh White for Sharecast.com.

Top Director Buys

Bridgepoint Group (reg S) (BPT) Director name: Jones,Adam Amount purchased: 100,000 @ 195.24p Value: £195,240.00

Staffline Group (STAF) Director name: Spain,Thomas Amount purchased: 600,000 @ 28.69p Value: £172,140.01

Trustpilot Group (TRST) Director name: Byng-Thorne,Zillah Amount purchased: 150,000 @ 92.60p Value: £138,900.00

Trustpilot Group (TRST) Director name: Blair,Adrian Amount purchased: 104,216 @ 94.42p Value: £98,398.66

Literacy Capital (BOOK) Director name: Dady,Kevin Amount purchased: 20,000 @ 490.00p Value: £98,000.00

Team17 Group (TM17) Director name: Whiting,Peter Amount purchased: 20,900 @ 308.90p Value: £64,560.10

Gsk (GSK) Director name: Bancroft,Charles Amount purchased: 3,382 @ $19.01 Value: $53,023.11

Eurocell (ECEL) Director name: Waters,Darren Amount purchased: 42,161 @ 118.00p Value: £49,749.98

Trustpilot Group (TRST) Director name: Blair,Adrian Amount purchased: 33,196 @ 94.43p Value: £31,346.98

Gsk (GSK) Director name: Symonds,Jonathan Amount purchased: 1,900 @ 1,526.00p Value: £28,994.00

Naked Wines (WINE) Director name: Pailing,Jack Amount purchased: 40,008 @ 65.00p Value: £26,005.20

Gsk (GSK) Director name: Sikka,Vishal Amount purchased: 1,580 @ $19.01 Value: $24,771.29

Trustpilot Group (TRST) Director name: Blair,Adrian Amount purchased: 25,212 @ 94.67p Value: £23,867.70

Eurocell (ECEL) Director name: Nelson ,Frank Amount purchased: 18,250 @ 114.00p Value: £20,805.00

Naked Wines (WINE) Director name: Devlin,Nicholas Amount purchased: 30,671 @ 65.20p Value: £19,997.49

Naked Wines (WINE) Director name: Pailing,Jack Amount purchased: 30,000 @ 60.00p Value: £18,000.00

Nexteq (NXQ) Director name: Penny,Duncan Amount purchased: 10,000 @ 122.00p Value: £12,200.00

Audioboom Group (BOOM) Director name: Tobin,Michael Amount purchased: 6,160 @ 160.00p Value: £9,856.00

Trustpilot Group (TRST) Director name: Blair,Adrian Amount purchased: 10,292 @ 95.71p Value: £9,850.47

Trustpilot Group (TRST) Director name: Blair,Adrian Amount purchased: 10,284 @ 95.78p Value: £9,850.43

Naked Wines (WINE) Director name: Pailing,Jack Amount purchased: 14,992 @ 65.50p Value: £9,819.76

Rockwood Strategic (RKW) Director name: Lamb ,Noel Amount purchased: 500 @ 1,725.00p Value: £8,625.00

Gsk (GSK) Director name: Barron ,Hal Amount purchased: 438 @ 1,901.28p Value: £8,327.58

Audioboom Group (BOOM) Director name: Maddock,Roger Amount purchased: 5,000 @ 157.88p Value: £7,894.00

Gsk (GSK) Director name: Rohner,Urs Amount purchased: 453 @ 1,528.80p Value: £6,925.46

Gsk (GSK) Director name: Dietz,Harry (Hal) C. Amount purchased: 440 @ $19.01 Value: $6,898.33

Gsk (GSK) Director name: Anderson,Elizabeth (Liz) McKee Amount purchased: 440 @ $19.01 Value: $6,898.33

Gsk (GSK) Director name: Beal,Anne Amount purchased: 440 @ $19.01 Value: $6,898.33

Gsk (GSK) Director name: Goodman,Jesse Amount purchased: 440 @ $19.01 Value: $6,898.33

Headlam Group (HEAD) Director name: Williams,Robin George Amount purchased: 2,090 @ 234.45p Value: £4,900.01

Naked Wines (WINE) Director name: Pailing,Jack Amount purchased: 6,813 @ 59.70p Value: £4,067.36

Cohort (CHRT) Director name: Walther,Simon Amount purchased: 365 @ 492.00p Value: £1,795.80

Cohort (CHRT) Director name: Thomis,Andrew Stephen Amount purchased: 365 @ 492.00p Value: £1,795.80

Wetherspoon (j.d.) (JDW) Director name: Hutson,John Amount purchased: 21 @ 706.44p Value: £148.35

Wetherspoon (j.d.) (JDW) Director name: Whitley ,Ben Amount purchased: 21 @ 706.44p Value: £148.35

Top Director Sells

Staffline Group (STAF) Director name: Spain,Thomas Amount sold: 1,514,050 @ 28.00p Value: £423,934.00

Coca-cola Hbc Ag (cdi) (CCH) Director name: Bogdanovic,Zoran Amount sold: 13,500 @ 2,305.00p Value: £311,174.99

Share this article

Related Sharecast Articles

Director dealings: Blue Coast raises stake in Everyman Media
(Sharecast News) - Everyman Media revealed on Thursday that Blue Coast had acquired 50,000 ordinary shares in the AIM-listed cinema group.
Director dealings: Angus Energy CEO ups stake
(Sharecast News) - Angus Energy revealed on Wednesday that chief executive Richard Herbert had acquired 5.0m ordinary shares in the AIM-listed onshore oil and gas development firm.
Director dealings: Abrdn CEO makes share sale
(Sharecast News) - Abrdn revealed on Monday that chief executive Stephen Bird had disposed of 29,942 ordinary shares in the FTSE 250-listed global investment company.
Director dealings: Redx Pharma CEO ups stake
(Sharecast News) - Redx Pharma revealed on Friday that chief executive Lisa Anson had acquired 399,000 ordinary shares in the AIM-listed clinical-stage biopharmaceutical firm.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.